Subacute thyroiditis Medical Services in China

Subacute thyroiditis, also known as de Quervain’s thyroiditis, is a self-limiting inflammatory disorder of the thyroid gland characterized by neck pain, transient thyrotoxicosis followed by hypothyroidism, and eventual spontaneous recovery in most cases. It is believed to be post-viral in origin—often preceded by an upper respiratory infection—and involves immune-mediated destruction of thyroid follicular cells, leading to leakage of preformed thyroid hormones into circulation. Histologically, it features granulomatous inflammation with multinucleated giant cells and lymphocytic infiltration, distinguishing it from autoimmune thyroiditis (e.g., Hashimoto’s) or painless thyroiditis. The pathogenesis centers on viral-triggered innate immune activation (e.g., via TLR3 or MDA5 pathways), resulting in localized thyroid inflammation without autoantibody production—anti-thyroid peroxidase (TPO) and thyroglobulin antibodies are typically negative or only mildly elevated. Epidemiologically, subacute thyroiditis affects approximately 4–5 per 100,000 individuals annually, with a strong female predominance (F:M ratio ~4–5:1) and peak incidence between ages 30 and 50. Risk factors include recent viral illness (e.g., coxsackievirus, mumps, Epstein-Barr virus, SARS-CoV-2), HLA-B35 positivity (a genetic susceptibility marker), and possibly seasonal variation (higher incidence in summer/fall). While not life-threatening, it significantly impairs quality of life: patients commonly report debilitating anterior neck pain radiating to the jaw or ears, low-grade fever, fatigue, palpitations, anxiety, insomnia, and emotional lability during the thyrotoxic phase; later, lethargy, cold intolerance, and depression may emerge during transient hypothyroidism. Pain often worsens with swallowing or neck movement and may persist for weeks. Though full thyroid function usually normalizes within 3–6 months, up to 5–10% develop permanent hypothyroidism requiring lifelong levothyroxine. Importantly, misdiagnosis as bacterial thyroiditis, Graves’ disease, or even malignancy can lead to unnecessary antibiotics, radioactive iodine, or surgery—underscoring the need for accurate clinical assessment, elevated erythrocyte sedimentation rate (ESR) or CRP, low radioactive iodine uptake on thyroid scan, and absence of TSH receptor antibodies. Patient education about its benign, self-resolving nature is critical to alleviate anxiety and reduce healthcare overutilization.

Subacute thyroiditis (SAT), also known as de Quervain’s thyroiditis, is a self-limiting inflammatory disorder of the thyroid gland typically triggered by a post-viral immune-mediated response. It presents with neck pain, fever, fatigue, and transient thyrotoxicosis followed by euthyroidism or, less commonly, transient hypothyroidism. Diagnosis relies on clinical assessment, elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), suppressed TSH, elevated free T4/T3 early in the course, low radioactive iodine uptake (<5% at 24 hours), and often ultrasonographic findings of heterogeneous hypoechoic areas with reduced vascularity. Given its benign, self-resolving nature—typically lasting 6–12 weeks—management focuses on symptom control, inflammation suppression, and monitoring for phase transitions rather than disease modification.

Conservative treatment forms the cornerstone of SAT management. Patients with mild symptoms—such as minimal neck discomfort, absence of systemic toxicity, and only modest biochemical abnormalities—may require no pharmacologic intervention beyond supportive care. This includes adequate hydration, rest, antipyretics (e.g., acetaminophen/paracetamol) for low-grade fever, and reassurance regarding the expected spontaneous resolution. Neck immobilization is unnecessary; however, patients are advised to avoid vigorous palpation or manipulation of the thyroid region to prevent exacerbation of local tenderness. Serial clinical evaluation every 2–4 weeks is essential to detect progression into the hypothyroid phase, which occurs in ~5–15% of cases and may necessitate temporary levothyroxine replacement. Importantly, conservative measures do not alter the natural history but significantly improve quality of life during the acute phase.

Pharmacologic therapy is indicated for moderate-to-severe symptoms—particularly significant pain, high-grade fever (>38.5°C), or profound malaise. First-line treatment is nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen (400–600 mg three times daily) or naproxen (500 mg twice daily), initiated for 1–2 weeks. Approximately 30–40% of patients achieve adequate symptomatic relief with NSAIDs alone. If NSAIDs fail or are contraindicated (e.g., peptic ulcer disease, chronic kidney disease, or aspirin-exacerbated respiratory disease), glucocorticoids are the definitive second-line option. Prednisone is administered orally at an initial dose of 25–40 mg/day for 1–2 weeks, followed by a slow, symptom-guided taper over 4–8 weeks (e.g., reducing by 5 mg every 5–7 days until discontinuation). Rapid improvement in pain and systemic symptoms within 24–72 hours strongly supports the diagnosis of SAT and predicts favorable steroid responsiveness. Thyroid hormone levels should be monitored monthly during treatment: TSH and free T4 are assessed to identify the onset of hypothyroidism, which may emerge during steroid taper or after cessation. Antithyroid drugs (e.g., methimazole) are contraindicated, as thyrotoxicosis results from hormone leakage—not increased synthesis—and carries no risk of thyroid storm. Beta-blockers (e.g., propranolol 10–40 mg three times daily) may be used short-term for symptomatic control of tachycardia, tremor, or anxiety during the thyrotoxic phase, but they do not address underlying inflammation.

Surgical treatment has no role in subacute thyroiditis. Thyroidectomy is neither indicated nor beneficial, as SAT is non-neoplastic, non-destructive in the long term, and does not confer malignancy risk. Surgery would expose patients to unnecessary morbidity—including recurrent laryngeal nerve injury, hypoparathyroidism, and cosmetic scarring—without altering disease trajectory. Similarly, radioiodine ablation is absolutely contraindicated due to the already markedly suppressed iodine uptake and lack of functional thyroid tissue hyperactivity. Interventional procedures such as fine-needle aspiration (FNA) are reserved solely for diagnostic uncertainty—e.g., when malignancy or abscess cannot be excluded—but are not therapeutic. In rare instances of persistent, steroid-refractory pain (>8 weeks despite appropriate taper), referral to a multidisciplinary pain service or consideration of short-course low-dose colchicine (0.5 mg twice daily for 2–4 weeks) may be explored off-label, though evidence remains limited.

Treatment advantages in China reflect integration of evidence-based endocrinology with robust healthcare infrastructure and evolving translational research. Major tertiary hospitals—especially those affiliated with Peking Union Medical College Hospital, Shanghai Jiao Tong University School of Medicine, and West China Hospital—offer rapid access to high-resolution thyroid ultrasound with elastography and automated ESR/CRP platforms, enabling same-day diagnostic stratification. Chinese endocrinologists routinely employ standardized steroid tapering protocols validated in multicenter domestic cohorts, minimizing relapse rates (<5%). Moreover, China’s National Medical Products Administration (NMPA) has approved cost-effective generic formulations of prednisone and levothyroxine, ensuring affordability and adherence. Telemedicine platforms integrated with national electronic health records facilitate longitudinal monitoring of thyroid function and symptom diaries, particularly valuable for rural patients. Importantly, traditional Chinese medicine (TCM) adjuncts—such as *Xiaoyao San* or *Yin Qiao San*—are sometimes used under dual supervision (endocrinologist + certified TCM physician) for supportive symptom modulation, although rigorous RCT data remain sparse and these are never substituted for anti-inflammatory therapy.

Recovery advice emphasizes patient education and proactive self-monitoring. Patients should be instructed to recognize red flags: worsening neck swelling with dysphagia/dyspnea (suggesting compressive hematoma), persistent fever >10 days despite steroids (raising concern for alternative infection), or new-onset palpitations with weight loss and atrial fibrillation (warranting urgent cardiology evaluation). Routine thyroid function testing is recommended at 6-week intervals until full normalization, then annually for 2 years to screen for late-onset autoimmune thyroid disease (SAT confers a 2–3-fold increased risk of subsequent Hashimoto’s thyroiditis). Lifestyle guidance includes avoiding excessive iodine intake (e.g., kelp supplements, iodized salt overload), maintaining balanced nutrition rich in selenium and zinc (modest evidence for antioxidant support), and gradual resumption of physical activity—avoiding heavy lifting or high-intensity exercise until pain and CRP normalize. Psychosocial support is integral: up to 30% of patients report anxiety related to misdiagnosis (e.g., confusion with thyroid cancer) or fear of permanent dysfunction; structured counseling and peer-led support groups hosted by provincial Endocrine Societies improve coping and adherence. With appropriate management, >95% of patients achieve full clinical and biochemical recovery without sequelae; recurrence is rare (<5%) and generally milder if it occurs.